Covid-19 roundup: Pfizer/BioNTech/Moderna test vaccines against new UK variant; Ocugen strikes deal for US rights to PhIII vaccine
Both Pfizer/BioNTech and Moderna have said their candidates should protect against a new variant of coronavirus that has been detected in the UK, and are conducting tests to prove it.
BioNTech CEO Ugur Sahin has said it’s “highly likely” that their vaccine developed with Pfizer will be effective against the new variant, which scientists worry could spread more easily than the current strain. There’s no evidence right now that the mutation causes more serious illness. But to be safe, multiple countries are blocking travel from the UK.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.